Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2001

01-08-2001 | Review Article

Clinical Applications for Maggots in Wound Care

Author: Dr Kosta Y. Mumcuoglu

Published in: American Journal of Clinical Dermatology | Issue 4/2001

Login to get access

Abstract

Maggot debridement therapy (MDT) was first introduced in the US in 1931 and was routinely used here until mid-1940s in over 300 hospitals. With the advent of antibacterials, maggot therapy became rare until the early 1990s, when it was re-introduced first in the US, and later in Israel, the UK, Germany, Sweden, Switzerland, Ukraine and Thailand.
Sterile maggots of the green bottle fly, Lucilia (Phaenicia) sericata, are used for MDT. Up to 1000 maggots are introduced in the wound and left for 1 to 3 days. MDT could be used for any kind of purulent, sloughy wound on the skin, independent of the underlying diseases or the location on the body for ambulatory as well as for hospitalized patients. One of the major advantages of MDT is that the maggots separate the necrotic tissue from the living tissue, making a surgical debridement easier. In 80 to 95% of the cases, a complete or significant debridement of the wound is achieved. As therapy progresses, new layers of healthy tissue are formed over the wounds. The offensive odor emanating from the necrotic tissue and the intense pain accompanying the wound decrease significantly. In a significant number of patients, an immediate amputation can be prevented as a result of MDT. In other cases, a more proximal amputation could be avoided. It is also possible that in patients with deep wounds, where septicemia is a serious threat, this can be prevented as a result of MDT.
The majority of patients do not complain of any major discomfort during the treatment. Psychological and esthetic considerations are obvious. Maggots can occasionally cause a tickling or itching sensation. Approximately 20 to 25% of the patients with superficial, painful wounds, complain of increased pain during treatment with maggots, and are treated with analgesics.
MDT has been proven to be an effective method for cleaning chronic wounds and initiating granulation. It is a simple, efficient, well tolerated and cost-effective tool for the treatment of wounds and ulcers, which do not respond to conventional treatment and surgical intervention.
Literature
1.
2.
Baer W.S. The treatment of chronic osteomyelitis with the maggot (larva of the blow fly). J Bone Joint Surg 1931; 13: 438–475
3.
McKeever D.C. Maggots in treatment of osteomyelitis. J Bone Joint Surg 1933; 15: 85–93
4.
Robinson W., Norwood V.H. The role of surgical maggots in the disinfection of osteomyelitis and other infected wounds. J Bone Joint Surg 1933; 15: 409–412
5.
Sherman R.A., Pechter E.A. Maggot therapy: a review of the therapeutic application of fly larvae in human medicine, especially for treating osteomyelitis. Med Vet Entomol 1988; 2: 225–230PubMedCrossRef
6.
Horn K.L., Cobb A.H., Gates G.A. Maggot therapy for subacute mastoiditis. Arch Otolaryngol 1976; 102: 377–379PubMedCrossRef
7.
Vistnes L.M., Lee R., Ksander G.A. Proteolytic activity of blowfly larvae secretions in experimental burns. Surgery 1981; 90: 835–841PubMed
8.
Pechter E.A., Sherman R.A. Maggot therapy: the surgical metamorphosis. Plast Reconstr Surg 1983; 72: 567–570PubMedCrossRef
9.
Bunkis J., Gherini S., Walton R.L. Maggot therapy revisited. West J Med 1985; 42: 554–556
10.
Teich S., Myers R.A.M. Maggot therapy for severe skin infections. South Med J 1986; 79: 1153–1155PubMedCrossRef
11.
Stoddard S.R., Sherman R.M., Mason B.A., et al. Maggot debridement therapy: an alternative treatment for nonhealing ulcers. J Am Podiatr Med Ass 1995; 85: 218–221
12.
Sherman R.A., Wyle F., Vulpe M. Maggot therapy for treating pressure ulcers in spinal cord injury patients. J Spinal Cord Med 1996; 18: 71–74
13.
Sherman R.A., My-Tien Tran J., Sullivan, R. Maggot therapy for venous stasis ulcers. Arch Dermatol 1996; 132: 254–256PubMedCrossRef
14.
Mumcuoglu K.Y., Lipo M., Ioffe-Uspensky I, et al. Maggot therapy for gangrene and osteomyelitis [in Hebrew]. Harefuah 1997; 132: 323–325PubMed
15.
Mumcuoglu, K.Y., Ingber A., Gilead L. et al. Maggot therapy for the treatment of diabetic foot ulcers. Diabetes Care 1998; 21: 2030–2031PubMedCrossRef
16.
Mumcuoglu K.Y., Ingber A., Gilead L., et al. Maggot therapy for the treatment of intractable wounds. Intl J Dermatol 1999; 38: 623–627CrossRef
17.
Sherman R.A., Hall M.J.R., Thomas S. Medicinal maggots: an ancient remedy for some contemporary afflictions. Annu Rev Entomol 2000; 45: 55–81PubMedCrossRef
18.
Thomas S., Jones M., Shutler S., et al. Making friends with maggots. Nursing Times 1996; 92: 76–82
19.
Wollf H., Hannson C. Larval therapy for a leg ulcer with methicillin-resistant Staphylococcus aureus. Acta Derm Venereol 1999; 79: 320–321CrossRef
20.
Russ M., Roesch K., Fleischmann W. Wound treatment with maggots: the Bietigheim experience. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 19
21.
Rufli T., Steffen I., Nuesch R., et al. Sepsis as a complication of maggot therapy. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 18
22.
Church J.C.T. Biosurgery: larval intervention in the chronic wound. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 7
23.
Andrews A., Jones M., Champion A. Larval therapy and wound management. Med Microbiol 1999; 18: 18–19
24.
Simmons S.W. The culture of fly larvae for use in maggot therapy: thesis in zoology and entomology. Iowa State College, Ames: 1938
25.
Weil G.C., Simon R.J., Sweadner W.R. Larval or maggot therapy in the treatment of acute and chronic pyogenic infections. Am J Surgery 1933; 19: 36–48CrossRef
26.
Sherman R.A., Wyle F.A. Low-cost, low-maintenance rearing of maggots in hospitals, clinics, and schools. Am J Trop Med Hyg 1996; 54: 38–41PubMed
27.
Sherman R.A. A new dressing design for treating pressure ulcers with maggot therapy. Plast Reconstruct Surg 1997; 100: 451–456CrossRef
28.
Fleischmann W., Thoener B. Biobag: a live wound-dressing containing maggots. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 8
29.
Sherman RA, Sherman JM-T, Gilead L, et al. Maggot debridement therapy in outpatients. Arch Phys Med Rehab. In press
30.
Jarvis A. Maggots in orthopaedics: past, present and future. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 11–12
31.
Robinson W. Ammonium bicarbonate secreted by surgical maggots stimulates healing in purulent wounds. Am J Surgery 1940; 47: 111–115CrossRef
32.
Robinson W. Stimulation of healing in non-healing wounds by allantoin occurring in maggot secretions and of wide biological distribution. J Bone Joint Surg 1935; 17: 267–271
33.
Courtenay M. Present day experience of larval therapy in the UK. Third International Conference on Biotherapy; 1998 May 24–27; Jerusalem, 9
34.
Messer F.C., McClellan R.H., Pittsburgh M.D. Surgical maggots. A study on their function in wound healing. J Lab Clin Med 1935; 20: 1219–1226
35.
Hobson R.P. On an enzyme from blow-fly larvae (Lucilia sericata) which digests collagen in alkaline solution. Biochem J 1931; 25: 1458–1463PubMed
36.
Senior B.W., Graham K., Stevenson J.H. An investigation into the antibacterial properties of maggots in the healing of chronic necrotic ulcers. Third International Conference on Biotherapy; 1998 May 24–27; Jerusalem, 34
37.
Ziffren S.E., Heist H.E., May S.C., et al. The secretion of callagenase by maggots and its implication. Ann Surgery 1957; 138: 932–934CrossRef
38.
Weil G.C., Simon R.J., Sweadner W.R. A biological, bacteriological and clinical study of larval or maggot therapy in the treatment of acute and chronic pyogenic infections. Am J Surg 1933; 19: 36–48CrossRef
39.
Simons S.W. The bactericidal properties of excretions of the maggot of Lucilia sericata. Bull Entomol Res 1935; 26: 559–563CrossRef
40.
Pavillard E.R., Wright E.A. An antibiotic from maggots. Nature 1957; 152: 916–917CrossRef
41.
Lappin-Scott H.M. Bacterial-maggot interactions in wound therapy. Third International Conference on Biotherapy; 1998 May 24–27; Jerusalem, 21
42.
Thomas S., Andrews A.M., Hay N.P., et al. The anti-microbial activity of maggot secretions: results of a preliminary study. J Tissue Viability 1999: 9: 127–132PubMed
43.
Robinson W., Norwood V.H. Destruction of pyogenic bacteria in the alimentary tract of surgical maggots implanted in infected wounds. J Lab Clin Med 1934; 19: 581–586
44.
Mumcuoglu KY, Miller J, Mumcuoglu M, et al. Destruction of bacteria in the digestive tract of the maggot of Lucilia sericata. J Med Entomol. In press)
45.
Friedman E., Shaharabany M., Ravin S., et al. Partially purified antibacterial agent from maggots displays a wide range of antimicrobial activity. Third International Conference on Biotherapy; 1998 May 24–27; Jerusalem, 14
46.
Harris P. Enzymes in secretions of maggots. Forth International Biotherapy Conference; 1999 Jun 10–11; Porthcawl, South Wales, 9
47.
Greenberg B. Model for destruction of bacteria in the midgut of blow fly maggots. J Med Entomol 1968; 5: 31–38PubMed
48.
Espinoza-Fuentes F.P., Terra W.R. Physiological adaptations for digesting bacteria. Water fluxes and distribution of digestive enzymes in Musca domestica larval midgut. Insect Biochem 1987; 17: 809–817CrossRef
49.
Robinson W. Use of urea to stimulate healing in chronic purulent wounds. Am J Surgery 1936; 33: 192–197CrossRef
50.
Livingston S.K. The therapeutic active principle of maggots. J Bone Joint Surg 1936; 18: 751–756
51.
Robinson W. Some therapeutic uses of insects and their products. J Econ Entomol 1937; 30: 41–48
52.
Robinson W., Baker F.L. The enzyme urease and occurrence of ammonia in maggot infected wounds. J Parasitol 1939; 25: 149–155CrossRef
53.
Mumcuoglu K.Y., Miller J., Ioffe-Uspensky I., et al. The potential of maggots to secrete cytokines in vitro. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 14–15
54.
Wollina U., Liebold K., Schmidt W., et al. Biosurgery supports granulation and debridement and improves oxygen supply in chronic wounds. Fifth International Conference on Biotherapy; 2000 Jun 29–Jul 1; Wurzburg, 24
55.
Reames M.K., Christensen C., Luce E.A. The use of maggots in wound debridement. Ann Plastic Surg 1988; 21: 1–4CrossRef
56.
Teich S., Myers R.A.M.. Maggot therapy for severe skin infections. South Med J 1986; 79: 1153–1155PubMedCrossRef
Metadata
Title
Clinical Applications for Maggots in Wound Care
Author
Dr Kosta Y. Mumcuoglu
Publication date
01-08-2001
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2001
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200102040-00003

Other articles of this Issue 4/2001

American Journal of Clinical Dermatology 4/2001 Go to the issue

Review Article

Role of Lasers and Photodynamic Therapy in the Treatment of Cutaneous Malignancy

Therapy in Practice

Leprosy

Review Article

Exogenous Ochronosis

Review Article

Drug-Induced Skin Pigmentation

Original Research Article

The Combination Formulation of Clindamycin 1% plus Benzoyl Peroxide 5% versus 3 Different Formulations of Topical Clindamycin Alone in the Reduction of Propionibacterium acnes

Pharmacovigilance

Cutaneous Drug Reaction Case Reports